Iterum Therapeutics will release Q4 and full year 2024 financial results on February 7, 2025, and host a conference call.
Quiver AI Summary
Iterum Therapeutics plc announced that it will release its fourth quarter and full year 2024 financial results on February 7, 2025, before U.S. markets open. A conference call, led by management at 8:30 a.m. ET, will discuss the financial results and provide a business update. Participants can access the call via specific phone numbers and an access code, or listen to an audio webcast available on the Company's website. Iterum is focused on developing advanced antibiotics, particularly sulopenem, which has shown effectiveness against multi-drug resistant pathogens and has received FDA approval for treating uncomplicated urinary tract infections in women. The Company has also obtained designations to expedite the development of its oral and IV formulations of sulopenem. More information is available on their website.
Potential Positives
- Iterum Therapeutics is set to release its fourth quarter and full year 2024 financial results, indicating transparency and ongoing communication with investors.
- The company has received FDA approval for its NDA for ORLYNVAH™ (oral sulopenem), expanding its product portfolio and potential market presence.
- Sulopenem has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for multiple indications, highlighting its importance in addressing serious public health concerns related to multi-drug resistant pathogens.
Potential Negatives
- The press release provides no information regarding quarterly or annual financial performance, which may raise concerns about the company's current financial health.
- The upcoming financial results conference call could indicate that investors may need clarity on the company's performance, potentially signaling previous underperformance or uncertainty.
- There is a lack of transparency about future product pipelines or additional developments beyond the approval of ORLYNVAH™, which might lead to skepticism about the company's growth prospects.
FAQ
When will Iterum Therapeutics release financial results?
Iterum Therapeutics will release its fourth quarter and full year 2024 financial results on February 7, 2025.
How can I access the Iterum conference call?
You can access the conference call by dialing 833-470-1428 or 404-975-4839 and using Access Code 719739.
What is the focus of Iterum Therapeutics?
Iterum Therapeutics focuses on developing next-generation oral and IV antibiotics for multi-drug resistant infections.
What is sulopenem?
Sulopenem is Iterum's novel penem anti-infective compound targeting various resistant bacteria with both oral and IV formulations.
What designations has sulopenem received?
Sulopenem has received FDA approval, Qualified Infectious Disease Product (QIDP), and Fast Track designations for seven indications.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ITRM Hedge Fund Activity
We have seen 10 institutional investors add shares of $ITRM stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 1,340,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $1,460,600
- NEW LEAF VENTURE PARTNERS, L.L.C. added 247,934 shares (+255.4%) to their portfolio in Q3 2024, for an estimated $270,248
- ALPINE GLOBAL MANAGEMENT, LLC added 64,833 shares (+inf%) to their portfolio in Q3 2024, for an estimated $70,667
- RENAISSANCE TECHNOLOGIES LLC removed 64,022 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $69,783
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 38,483 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $41,946
- XTX TOPCO LTD added 33,040 shares (+inf%) to their portfolio in Q3 2024, for an estimated $36,013
- APOLLON FINANCIAL, LLC added 25,500 shares (+11.3%) to their portfolio in Q4 2024, for an estimated $45,135
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DUBLIN, Ireland and CHICAGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2024 financial results before the open of the U.S. financial markets on Friday, February 7, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 719739. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/118185211 . The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com .
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
[email protected]